1.
Mult Scler
; 29(9): 1066-1067, 2023 08.
Artículo
en Inglés
| MEDLINE
| ID: mdl-37489564
2.
Mult Scler J Exp Transl Clin
; 7(2): 20552173211013831, 2021.
Artículo
en Inglés
| MEDLINE
| ID: mdl-34123391
RESUMEN
Ocrelizumab is often used as an alternative therapy in natalizumab-treated MS patients at risk for progressive multifocal leukoencephalopathy (PML). Our objective was to assess efficacy and safety of JC-virus positive patients switching (either directly or indirectly) from natalizumab to ocrelizumab. Forty-two patients were included from an observational cohort (median follow-up 21 months). No evidence of disease activity was found in 83% of direct switchers and 50% of indirect switchers. Two direct switchers were diagnosed with carry-over PML. Our data support a direct switch for adequate disease suppression, although carry-over PML illustrates the dilemma when choosing between a direct or indirect switch.